|
    APLS U.S.: Nasdaq

    Apellis Pharmaceuticals Inc.

    APLSUS
    Open
    Back To Top
    Last Updated: Jun 23, 2021 11:50 a.m. EDT Real time quote

    $ 65.03

    1.31 2.06%
    Previous Close
    $63.72
    Advanced Charting
    • $
    • %
    • Vol
    Volume: 234K 65 Day Avg: 761.21K
    31% vs Avg
    63.50 Day Range 65.06
    25.49 52 Week Range 65.67

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    APLS Overview

    Performance

    5 Day
    • 8.95%
    1 Month
    • 25.83%
    3 Month
    • 59.39%
    YTD
    • 13.69%
    1 Year
    • 110.38%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 16 Full Ratings

    Recent News

    • eLesor
    • Dow Jones

    Apellis Pharmaceuticals Shares Rise 19% After FDA Approves Empaveli

    Apellis Pharmaceuticals price target raised to $104 from $78, stock rated strong buy

    Read full story

    Bull trend pauses: U.S. benchmarks digest rally to latest record close

    Apellis stock price target raised to $87 from $50 at J.P. Morgan

    Apellis Pharmaceuticals started at buy with $40 stock price target at Stifel Nicolaus

    Shares of Apellis rise on clinical data for rare blood disease drug

    Apellis Pharmaceuticals started at strong buy with $86 stock price target at Raymond James

    Apellis Pharmaceuticals upgraded to neutral from underperform at Wedbush

    Apellis Pharmaceuticals stock price target raised to $62 from $52 at Oppenheimer

    Read full story

    Apellis Stock Soars After Head-to-Head Drug Trial Vs Alexion

    Apellis stock soars on positive data for potential Soliris competitor

    Apellis Pharmaceuticals upgraded to overweight from neutral at J.P. Morgan

    Apellis Pharmaceuticals started at outperform with $52 stock price target at Oppenheimer

    Apellis Pharmaceuticals downgraded to neutral from overweight at J.P. Morgan

    Apellis Pharmaceuticals downgraded to neutral from buy at B. Riley FBR

    Apellis Pharmaceuticals started at overweight with $31 stock price target at J.P. Morgan

    Apellis Pharma, Sogou enjoy gains in their trading debut

    Apellis Pharma shares up 0.9% in their trading debut

    Apellis Pharma and Chinese search engine Sogou to start trading later Thursday after IPOs

    Apellis Pharma prices IPO at $14 a share, midpoint of range

    • Other News
    • Press Releases

    Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study

    on Zacks.com

    Apellis Pharmaceuticals (APLS) Receives a Buy from Stifel Nicolaus

    on SmarterAnalyst

    Amicus, Bloomin’ Brands, Seagate and More Friday Afternoon Analyst Calls

    on 247WallSt.com

    Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug

    on Zacks.com

    Is the Options Market Predicting a Spike in Apellis (APLS) Stock?

    on Zacks.com

    Company News for May 18, 2021

    on Zacks.com

    Needham Gives a Buy Rating to Apellis Pharmaceuticals (APLS)

    on SmarterAnalyst

    Apellis' (APLS) Blood Disorder Drug Empaveli Gets FDA Nod

    on Zacks.com

    Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Travere Therapeutics (TVTX) and Motus Gi Holdings (MOTS)

    on SmarterAnalyst

    Apellis Pharmaceuticals (APLS) Receives a Buy from Raymond James

    on SmarterAnalyst

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

    on InvestorPlace.com

    Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Sio Gene Therapies (SIOX)

    on SmarterAnalyst

    Credit Suisse Keeps a Hold Rating on Apellis Pharmaceuticals (APLS)

    on SmarterAnalyst

    Apellis Pharmaceuticals (APLS) Received its Third Buy in a Row

    on SmarterAnalyst

    BMO Capital Maintains a Buy Rating on Apellis Pharmaceuticals (APLS)

    on SmarterAnalyst

    Apellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus

    on Zacks.com

    Apellis Pharmaceuticals (APLS) Received its Third Buy in a Row

    on SmarterAnalyst

    Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Misses Revenue Estimates

    on Zacks.com

    Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's Why

    on Zacks.com

    Goldman Sachs: These 2 Stocks Are Poised to Double (or More)

    on TipRanks.com

    Apellis Pharmaceuticals Inc.

    Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

    Competitors

    Name Chg % Market Cap
    Profarma Distribuidora de Produtos Farmaceuticos S/A Ord 4.81% R$815.36M
    Joey New York Inc. -16.67%
    1pm Industries Inc. 0.00%
    McKesson Corp. -0.72% $29.4B
    Competitor Data Provided ByCapital Cube Logo